Search

everythinglearnresearchcommunity

for

Search:↓

Flutamide combined with an LHRH agonist effectively inhibits prostate growth, suggesting it could treat prostate cancer.

Birth control pills combined with bicalutamide are more effective at reducing excessive hair growth in women with PCOS than birth control pills alone.

Combining flutamide and finasteride can reduce prostate weight and tumor growth, potentially benefiting treatments needing optimal DHT inhibition.

Dihydrotestosterone can be made from dehydroepiandrosterone in skin cells without needing testosterone.

The new compounds moderately block a specific enzyme and strongly counteract a male hormone, suggesting potential for treating certain male-related health conditions.

Androgenetic alopecia is a common hair loss condition caused by testosterone effects on hair follicles, leading to thinner, shorter, and less pigmented hair, diagnosed using scalp dermoscopy and treated with topical minoxidil, antiandrogen agents, and 5-alpha reductase inhibitors.

After menopause, some women lose scalp hair and gain facial hair, with patterns suggesting different underlying causes.

Minoxidil can reduce functions related to androgen receptors.

Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.

New treatments are being explored to slow or reverse hereditary hair loss.

Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.

Blood tests for tumor cells could improve prostate cancer diagnosis and treatment; hair loss severity linked to a gene affecting prostate conditions.

Anti-androgen therapy may boost immunity but increases injection site pain in vaccinated patients.

Healthcare providers need better education and resources to give competent and sensitive care to transgender patients.

Testosterone affects androgen receptors and lipid storage in cells, while DHEA does not convert to testosterone or affect these receptors in the same way.

Women with more body hair tend to have thicker belly fat and more metabolic health issues.

Effective treatments for excessive body hair in women include drugs that block androgens, sometimes combined with oral contraceptives.

Male androgenetic alopecia involves hair follicle miniaturization due to DHT, with potential treatments using inhibitors and blockers.

A new compound, 3a, effectively fights prostate cancer better than finasteride.

Excessive body hair in women can be caused by various conditions and treated with medication like Diane® 35 or androgen blockers.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Male pattern hair loss may be linked to the developmental origins of hair follicles.

The chapter explains the causes of excessive hair growth and masculinization in women and how to measure hormone levels related to these conditions.

Antiandrogens are the main treatment for hirsutism, with individualized care and safe, affordable options needed.

CE-PTG detects early hair follicle issues in balding areas, helping measure male hair loss.

Androgens can both promote and prevent hair growth due to differences in gene expression in hair follicles.

The document concludes that hirsutism can be managed with various treatments tailored to the individual, potentially improving quality of life.

Different levels of microRNAs in different parts of the scalp can cause male pattern baldness.

Androgen therapy can help with symptoms like low libido in women, but more research is needed to understand its long-term safety and effects on health.

Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.